Regulatory Roundup: USP Hosts Symposium on Science and Standards - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: USP Hosts Symposium on Science and Standards


The US Pharmacopeia Convention (USP) held its first Science and Standards Symposium in Sao Paulo, Brazil, on August 23–24, 2012. The meeting focused on the importance of the Biopharmaceutics Classification System. Almost 300 regulators, academics, pharmaceutical manufacturers, and quality control experts from Latin American countries and the US attended the Symposium, which was cosponsored by the University of Sao Paulo.

According to a press release, Roger Williams, MD, chief executive officer of USP, closed the meeting by asking the attendees to think about a “global system of interchangeable products.” Williams stated, “If you have a highly soluble drug substance that is rapidly dissolving, it should be optimally bioavailable. Then, if you have two different products with the same active ingredients that are both optimally bioavailable, they should be bioequivalent.” According to release, “drug product monographs in the new USP Medicines Compendium, coupled with labeling, might advance the general approach for the classification and regulation of biopharmaceuticals.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
31%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here